Welcome to our dedicated page for Gilead Sciences SEC filings (Ticker: GILD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Gilead Sciences, Inc. (Nasdaq: GILD) is a Delaware‑incorporated biopharmaceutical company whose common stock is registered on The Nasdaq Global Select Market. As an SEC‑reporting issuer, Gilead files a range of regulatory documents that provide detailed insight into its financial condition, governance and material events. This page aggregates GILD’s SEC filings and pairs them with AI‑generated summaries to help readers understand the key points in complex disclosures.
For Gilead, Form 10‑K annual reports and Form 10‑Q quarterly reports are central sources of information on its HIV, viral hepatitis, COVID‑19, oncology and inflammation businesses, including segment discussions, risk factors and research and development spending. Form 8‑K current reports capture specific developments such as quarterly financial results, amendments to bylaws, executive leadership changes and significant agreements. Recent 8‑K filings, for example, have disclosed financial results for particular quarters, updates to the company’s bylaws governing director nominations and stockholder proposals, patent settlements related to Biktarvy, and changes in senior corporate affairs and legal roles.
Investors can also use this page to access proxy statements for information on board structure and executive compensation, and Form 4 insider transaction reports to track trades by directors and officers. Because Gilead is not classified as an emerging growth company, its filings follow the full disclosure requirements applicable to large, established issuers.
Stock Titan enhances GILD filings with AI‑powered explanations that highlight material items, translate technical accounting and legal language into plain terms, and surface topics such as governance changes, litigation updates or collaboration agreements. Real‑time ingestion from EDGAR means new Gilead filings appear quickly, while the AI layer helps readers focus on what changed, why it matters for the company’s HIV, antiviral and oncology franchises, and how it may affect shareholders.
Gilead Sciences (GILD) disclosed insider activity by its EVP, Corporate Affairs & GC, on 11/12/2025 pursuant to a Rule 10b5‑1 trading plan adopted on August 13, 2025. The officer exercised non‑qualified stock options and sold the resulting shares the same day.
Exercises were for 17,181 shares at $75.12, 35,965 shares at $60.75, and 500 shares at $60.75, followed by sales of equal amounts. Sale prices included $124 and weighted‑average prices of $122.302 and $122.904, with transaction ranges of $121.87–$122.83 and $122.88–$122.92. After these trades, 43,676 common shares were beneficially owned directly.
Gilead Sciences, Inc. filed a Form 13F reporting its institutional holdings. The filing is a 13F Holdings Report signed by Andrew D. Dickinson, Executive Vice President and Chief Financial Officer, dated 11-13-2025.
The report lists 9 information-table entries with a total value of $1,791,467,184 and names one other included manager, Gilead Therapeutics A1 Unlimited Co (Form 13F File No. 028-25083).
Gilead Sciences (GILD) filed its Q3 2025 10‑Q, reporting total revenue of $7.77 billion, up from $7.55 billion a year ago, and diluted EPS of $2.43 versus $1.00. Net income rose to $3.05 billion from $1.25 billion as operating income improved to $3.33 billion, reflecting lower charges versus last year and higher royalty and contract revenue.
Product sales were $7.35 billion (slightly below $7.52 billion last year). HIV remained the core driver at $5.28 billion, led by Biktarvy at $3.69 billion. Liver Disease rose to $819 million, while Veklury declined to $277 million. Oncology product sales were $788 million, with Cell Therapy at $432 million and Trodelvy at $357 million. The company recognized $400 million of previously constrained revenue tied to a sale of certain intellectual property, lifting royalty/contract revenue to $424 million. Cash and equivalents were $7.33 billion; operating cash flow for the nine months was $6.69 billion. Shares outstanding were 1,240,679,623 as of October 31, 2025.
Gilead Sciences announced its financial results for the quarter ended September 30, 2025 and furnished a press release as Exhibit 99.1.
The company presented GAAP and non-GAAP measures, with reconciliations provided in the press release tables. The information in Item 2.02 and Exhibit 99.1 is furnished and shall not be deemed “filed” under the Exchange Act, nor incorporated by reference.
Gilead Sciences (GILD) insider filing: Chairman & CEO Daniel P. O’Day reported open‑market sales totaling 10,000 shares on 10/28/2025 under a Rule 10b5‑1 trading plan adopted on February 28, 2025. The transactions were coded “S”.
He sold 7,978 shares at an average price of $119.5371 and 2,022 shares at $118.8223. Following the sales, he beneficially owns 581,203 shares directly, down from 583,225 before these trades. The filing notes price ranges for each trade, with full breakdowns available upon request to the company, the SEC, or shareowners.
Gilead Sciences (GILD): Officer equity transaction reported
On 10/25/2025, an officer of Gilead Sciences (title: EVP, Corporate Affairs & GC) reported the conversion of 515 restricted stock units into common stock (transaction code M) and the disposition of 241 shares at $120.94 (transaction code F). Following these transactions, the officer directly owned 43,676 shares of common stock.
The filing also shows 19,816 restricted stock units beneficially owned after the reported transaction. The RSUs vest over four years: 25% on the first anniversary of grant, then 6.25% quarterly until fully vested.
Gilead Sciences (GILD) CFO Andrew D. Dickinson reported an open‑market sale of 2,500 shares of common stock at $118.08 on October 15, 2025. The filing notes the trade was made under a Rule 10b5-1 trading plan adopted on August 29, 2024.
Following the transaction, Dickinson beneficially owns 157,055 shares, held directly.
Gilead Sciences (GILD) disclosed an insider transaction by Chief Commercial Officer Johanna Mercier. On 10/15/2025, she sold 3,000 shares of common stock at $118.08 per share (transaction code S). After the sale, she beneficially owned 110,193 shares, held directly.
The filing states the trade was made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.
Gilead Sciences, Inc. has entered into settlement agreements to resolve patent litigation over its HIV treatment Biktarvy with generic manufacturers Lupin Ltd., Cipla Ltd. and Laurus Labs Ltd. These companies had sought U.S. approval to sell generic versions of Biktarvy.
Under the agreements, which include standard acceleration provisions, no generic entry is expected in the United States before April 1, 2036 for Biktarvy tablets containing bictegravir 50 mg, emtricitabine 200 mg and tenofovir alafenamide 25 mg. Gilead also reiterates that these statements are forward-looking and subject to risks such as intellectual property challenges, litigation outcomes and regulatory changes.
Daniel P. O'Day, Chairman & CEO of Gilead Sciences (GILD), reported sales of common stock on 09/29/2025 under a pre-established Rule 10b5-1 trading plan adopted February 28, 2025. The Form 4 shows two sale transactions: 8,039 shares sold at prices reported in a range around $110.97–$111.92 and 1,961 shares sold at prices reported in a range around $112.00–$112.55. After these transactions the reporting person beneficially owned 591,203 shares. The filing was submitted under Section 16 and executed by power of attorney. The disclosure states that full per-price breakdowns are available on request.